Opin vísindi
→
Browsing by Author

Browsing by Author "Schmiegelow, Kjeld"

Now showing items 1-3 of 3

Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study

Helenius, Marianne; Vaitkeviciene, Goda; Abrahamsson, Jonas; Jónsson, Ólafur Gisli; Lund, Bendik; Harila-Saari, Arja; Vettenranta, Kim; Mikkel, Sirje; Stanulla, Martin; Lopez-Lopez, Elixabet; Waanders, Esmé; Madsen, Hans O; Marquart, Hanne Vibeke; Modvig, Signe; Gupta, Ramneek; Schmiegelow, Kjeld; Nielsen, Rikke Linnemann (2022-03-22)

Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood. ...
Genome-wide association meta-analysis of single-nucleotide polymorphisms and symptomatic venous thromboembolism during therapy for acute lymphoblastic leukemia and lymphoma in caucasian children

Mateos, Marion K.; Tulstrup, Morten; Quinn, Michael C.J.; Tuckuviene, Ruta; Marshall, Glenn M.; Gupta, Ramneek; Mayoh, Chelsea; Wolthers, Benjamin O.; Barbaro, Pasquale M.; Ruud, Ellen; Sutton, Rosemary; Huttunen, Pasi; Revesz, Tamas; Trakymiene, Sonata S.; Barbaric, Draga; Tedgård, Ulf; Giles, Jodie E.; Alvaro, Frank; Jonsson, Olafur G.; Mechinaud, Françoise; Saks, Kadri; Catchpoole, Daniel; Kotecha, Rishi S.; Dalla-Pozza, Luciano; Chenevix-Trench, Georgia; Trahair, Toby N.; Macgregor, Stuart; Schmiegelow, Kjeld (2020-05-19)

Symptomatic venous thromboembolism (VTE) occurs in five percent of children treated for acute lymphoblastic leukemia (ALL), but whether a genetic predisposition exists across different ALL treatment regimens has not been well studied. Methods: We ...
Thiopurine Enhanced ALL Maintenance (TEAM) : study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol

Toksvang, Linea Natalie; Als-Nielsen, Bodil; Bacon, Christopher; Bertasiute, Ruta; Duarte, Ximo; Escherich, Gabriele; Helgadottir, Elín Anna; Johannsdottir, Inga Rinvoll; Jónsson, Ólafur G.; Kozlowski, Piotr; Langenskjöld, Cecilia; Lepik, Kristi; Niinimäki, Riitta; Overgaard, Ulrik Malthe; Punab, Mari; Räty, Riikka; Segers, Heidi; van der Sluis, Inge; Smith, Owen Patrick; Strullu, Marion; Vaitkevičienė, Goda; Wik, Hilde Skuterud; Heyman, Mats; Schmiegelow, Kjeld (2022-05-02)

Background: A critical challenge in current acute lymphoblastic leukemia (ALL) therapy is treatment intensification in order to reduce the relapse rate in the subset of patients at the highest risk of relapse. The year-long maintenance phase is essential ...

Now showing items 1-3 of 3

Search Opin vísindi

Browse

All of Opin vísindi
- Communities & Collections
- Authors
- Titles
- Subjects
- Departments
- School
- DOI
- Journal title

Browsing by Author "Schmiegelow, Kjeld"

Browsing by Author "Schmiegelow, Kjeld"

Search Opin vísindi

Browse

All of Opin vísindi

About

My Account